Skip to main content

Table 3 Crude incidence rates and incidence rate ratios of 11 study outcomes among asthma patients, stratified by non-use, ever use, and current use of oral prednisolone

From: Adverse events profile of oral corticosteroids among asthma patients in the UK: cohort study with a nested case-control analysis

Use of oral prednisolone Bone-related conditions Hypertension Peptic ulcer Severe
infections
Herpes zoster DM2 Cataract Glaucoma CKD Affective disorders Cardiovascular events
Non-use (reference)
 Cases, n 6174 5867 591 10,115 2882 3534 3639 1057 6034 3602 2868
 Person-years 509,914 493,646 631,164 567,254 614,128 609,903 618,128 633,404 616,192 402,782 607,320
 IR/ 1000 person-years (95% CI) 12.1 (11.8–12.4) 11.9 (11.6–12.2) 0.9 (0.9–1.0) 17.8 (17.5–18.2) 4.7 (4.5–4.9) 5.8 (5.6–6.0) 5.9 (5.7–6.1) 1.7 (1.6–1.8) 9.8 (9.5–10.0) 8.9 (8.7–9.2) 4.7 (4.5–4.9)
Ever use
 Cases, n 2753 2295 245 6077 1293 1661 1717 416 2791 1363 1160
 Person-years 172,484 159,919 219,711 177,156 210,560 210,152 212,161 220,804 208,916 122,796 209,638
 IR/1000 person-years (95% CI) 16.0 (15.4–16.6) 14.4 (13.8–14.9) 1.1 (1.0–1.3) 34.3 (33.4–35.2) 6.1 (5.8–6.5) 7.9 (7.5–8.3) 8.1 (7.7–8.5) 1.9 (1.7–2.1) 13.4 (12.9–13.9) 11.1 (10.5–11.7) 5.5 (5.2–5.9)
 IRR (95% CI) 1.3 (1.3–1.4) 1.2 (1.2–1.3) 1.2 (1.0–1.4) 1.9 (1.9–2.0) 1.3 (1.2–1.4) 1.4 (1.3–1.4) 1.4 (1.3–1.5) 1.1 (1.0–1.3) 1.4 (1.3–1.4) 1.2 (1.2–1.3) 1.2 (1.1–1.3)
Current use
 Cases, n 533 451 51 2268 257 398 272 62 541 269 236
 Person-years 29,141 27,032 36,864 29,074 35,586 35,468 35,723 37,125 35,364 19,803 35,269
 IR/1000 person-years (95% CI) 18.3 (16.7–19.8) 16.7 (15.1–18.2) 1.4 (1.0–1.8) 78.0 (74.8–81.2) 7.2 (6.3–8.1) 11.2 (10.1–12.3) 7.6 (6.7–8.5) 1.7 (1.3–2.1) 15.3 (14.0–16.6) 13.6 (12.0–15.2) 6.7 (5.8–7.5)
 IRR (95% CI) 1.5 (1.4–1.6) 1.4 (1.3–1.5) 1.5 (1.1–2.0) 4.4 (4.2–4.6) 1.5 (1.4–1.7) 1.9 (1.7–2.2) 1.3 (1.1–1.5) 1.0 (0.8–1.3) 1.6 (1.4–1.7) 1.5 (1.3–1.7) 1.4 (1.2–1.6)
  1. Abbreviations: CI confidence interval, CKD chronic kidney disease, DM2 diabetes mellitus type 2, IR incidence rate, IRR incidence rate ratio